% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Cairat:136991,
author = {M. Cairat and A. Fournier and N. Murphy and C. Biessy and
A. Scalbert and S. Rinaldi and A. Tjønneland and A. Olsen
and K. Overvad and P. Arveux and M.-C. Boutron-Ruault and C.
Cadeau and R. Turzanski-Fortner$^*$ and R. Kaaks$^*$ and H.
Boeing and K. Aleksandrova and P. H. M. Peeters and C. H.
Van Gils and N. J. Wareham and K.-T. Khaw and D. Aune and E.
Riboli and M. J. Gunter and L. Dossus},
title = {{N}onsteroidal anti-inflammatory drug use and breast cancer
risk in a {E}uropean prospective cohort study.},
journal = {International journal of cancer},
volume = {143},
number = {7},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2018-01419},
pages = {1688 - 1695},
year = {2018},
abstract = {Experimental studies have shown a protective effect of
nonsteroidal anti-inflammatory drugs (NSAIDs) on breast
cancer development. However, results from epidemiological
cohort studies are less consistent. Our objective was to
assess the association between NSAID use and breast cancer
risk within the European Prospective Investigation into
Cancer and Nutrition (EPIC). EPIC is a prospective cohort
study initiated in 1992 in 10 European countries.
Self-reported information on NSAID use at baseline has been
collected in five EPIC countries. Multivariable Cox
regression models were used to estimate hazard ratios for
the association of NSAID use with breast cancer incidence
with adjustment for potential confounders. We also assessed
effect modification by breast cancer risk factors and
examined the associations within specific breast cancer
subtypes. Among the 140,981 women included in the analysis,
$7\%$ were regularly using NSAIDs at baseline. During a
median follow-up time period of 13 years, 7,379 incident
breast cancer cases were diagnosed (816 in situ and 6,563
invasive). There were no statistically significant
associations between NSAID use and breast cancer risk,
overall and by subtypes. However, a statistically
significant interaction was observed for invasive cases
between NSAID use and ever use of menopausal hormonal
therapy (MHT) among postmenopausal women [MHT users: HRNSAID
use = 0.84 (0.73-0.96); non MHT users: HRNSAID use
= 1.08 (0.93-1.25); pinteraction = 0.05]. Our
results indicate potential effect modification of MHT use on
the association between use of NSAIDs and breast cancer risk
which deserves in-depth investigation in studies with
accurate data on both NSAID and MHT use.},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:29707771},
doi = {10.1002/ijc.31570},
url = {https://inrepo02.dkfz.de/record/136991},
}